Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Sponsor

Zhejiang University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05731726

Collaborator

(none)

Enrollment

Arm

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Colorectal cancer of Mismatch Repair-proficient (pMMR)/ Microsatellite Stability (MSS) accounts for approximately 85% of all colorectal cancer patients, which might be insensitive to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy, such as CAPEOX regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Celecoxib, a COX-2 inhibitor, can improve the immune microenvironment and have a potential to synergy with immunotherapy. Chemotherapy can improve the immunogenicity of cancer cells that might enhance the efficacy of immunotherapy. The aim of this study is to explore whether chemotherapy and cyclooxygenase (COX) inhibitors combined with anti-PD-1 monoclonal antibody (mAb) could improve efficacy for resectable colorectal cancer patient with the pMMR/MSS phenotype.

Condition or Disease	Intervention/Treatment	Phase
pMMR MSS MSI-L Locally Advanced Rectal Carcinoma	Drug: Serplilumab Drug: Capecitabine Drug: Oxaliplatin Drug: Celecoxib	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Study to Explore the Neoadjuvant Treatment of Serplulimab Combined With CAPEOX + Celecoxib in the Treatment of Locally Advanced Rectal Cancer

Anticipated Study Start Date :

Feb 20, 2023

Anticipated Primary Completion Date :

Feb 20, 2024

Anticipated Study Completion Date :

Feb 20, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Serplulimab+CAPEOX+celecoxib articipants will receive serplulimab 300 mg every 3 weeks (Q3W) concurrently with CAPEOX regimen: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine, 1000mg/m2, PO, BID, day1-14, q3w and celecoxib, 200mg, PO, BID, day1-21, q3w. Treatment repeats every 3 weeks for 6-8 cycles followed by surgery (total mesorectal excision, TME).	Drug: Serplilumab Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc. 300 mg, q3w Other Names: HLX10 Drug: Capecitabine Given PO Other Names: Xeloda Drug: Oxaliplatin Given IV Other Names: OHP Drug: Celecoxib celebrex Other Names: Given PO

Arm

Intervention/Treatment

Experimental: Serplulimab+CAPEOX+celecoxib

articipants will receive serplulimab 300 mg every 3 weeks (Q3W) concurrently with CAPEOX regimen: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine, 1000mg/m2, PO, BID, day1-14, q3w and celecoxib, 200mg, PO, BID, day1-21, q3w. Treatment repeats every 3 weeks for 6-8 cycles followed by surgery (total mesorectal excision, TME).

Drug: Serplilumab

Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc. 300 mg, q3w

Other Names:

HLX10

Drug: Capecitabine

Given PO

Other Names:

Xeloda

Drug: Oxaliplatin

Given IV

Other Names:

OHP

Drug: Celecoxib

celebrex

Other Names:

Given PO

Outcome Measures

Primary Outcome Measures

Pathological complete response rates [1 year]
Proportion of patients experiencing a pCR to perioperative PD-1 antibody

Secondary Outcome Measures

Major pathological response rates [1 year]
The proportion of patients experiencing a major pathological response to perioperative PD-1 antibody
Rate of clinical complete response rate (cCR) [1 year]
Proportion of patients experiencing a cCR to perioperative PD-1 antibody
R0 resection rates [1 year]
The proportion of patients achieved a complete resection with negative margin
Treatment-related adverse events. [1 year]
Assessed by evaluation of treatment-related adverse events.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Willing and able to provide written informed consent.
Male or female subjects ≧ 18 years ≦ 75 of age.
Histological or cytological documentation of adenocarcinoma of the rectum.
No previous any systemic anticancer therapy for rectal cancer disease.
The lower margin of the tumor is less than 10cm from the anus verge.
cT3N1M0, T4N0-1M0 MSS.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
At least one measurable lesion was evaluated according to RECIST 1.1.
Eligible tumor tissues were identified for MSI/MMR assays.
Expected survival of at least 3 months.
Hepatitis B Surface Antigen (HBsAg) (-) and Hepatitis B Core Antibody (HBcAb) (-).

If HBsAg (+) or HBcAb (+), HBV-DNA must be less than 2500 copies/mL or 500 IU/mL to be enrolled.

Patients with HCV antibody (-) or HCV-RNA negative can be enrolled. Aspartate aminotransferase (AST) must be ≤ 3 x ULN for the lab. If HCV-RNA is positive, patients with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) performed ≤3×ULN could be enrolled. Patients infected with both hepatitis B virus and hepatitis C virus should be excluded (positive for HBsAg or HBcAb and positive for HCV antibodies).

Exclusion Criteria:

Patients with recurrent rectal cancer or a history of pelvic radiotherapy.
Patients with a history of inflammatory bowel disease.
Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease (HIV1 antibody, HIV2 antibody, HTLV1 antibody positive) should be excluded.
Patients who are preparing for or have previously received an organ or bone marrow transplant.
History of myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms in women) in the 6 months prior to randomization (QTc interval calculated by Fridericia formula).
According to New York College of Cardiology (NYHA) standards for Grade III-IV cardiac insufficiency or cardiac color ultrasound: left ventricular ejection fraction (LVEF) <50%.Poor hypertension control (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.

Patients with active tuberculosis.

The patients had previously been treated with other antibodies/drugs that target immune checkpoints, such as PD-1, PD-L1, and cytotoxic T lymphocyte-associated Antigen 4 (CTLA-4).
Patients are participating in other clinical studies, or plan to start this study treatment less than 14 days from the end of the previous clinical study.
Uncontrolled tumor-related pain.

11.A known history of severe allergy to any monoclonal antibody. 12.Known to be allergic to any oxaliplatin and capecitabine ingredients. 13.Pregnant or lactating women. 14.The investigators determined that the patient had other factors that might have led to the early termination of the study.